chrisvoncsefalvay/vaers-outcomes huggingface dataset:
At 17 days, I can see a red mark; I have a scab at the injection site 9 days after vaccination; Cold sore outbreak in the corner of my mouth 6 days after vaccination; couple days after vaccination I noticed my joints felt crunchy, like there was plastic wrap in them.; noticed a small scab there that was still kind of oozing a bit; If I push on the muscle there it's slightly sore; the other arm is not.; This is a spontaneous report from a contactable consumer (patient). A 50-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in left arm on 06Apr2021 at 13:45 (Lot Number: EW0151) as SINGLE DOSE for covid-19 immunization.  Medical history included cold sore outbreak in the corner of mouth from an unknown date (had them before in the same spot, but less than once a year and usually a lot smaller). The patient's concomitant medications were not reported.  The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 12Apr2021, the patient had cold sore outbreak in the corner of his mouth 6 days after vaccination. On 15Apr2021, the patient had scab / small sore at the injection site 9 days after vaccination. On an unspecified date of Apr2021, about a week after vaccination, the patient noticed a small scab there that was still kind of oozing a bit. The patient also reported that, on an unspecified date in Apr2021, if he pushed on the muscle there it was noticed that the muscle was slightly sore; the other arm was not; couple days after vaccination he noticed his joints felt crunchy, like there was plastic wrap in them. 15 days after vaccination, he still had a scab. At 17 days, on 23Apr2021, he saw a red mark where the scab was formed. No corrective measures were taken by the patient. The outcome was reported as not recovered for the event cold sore mouth, vaccination site scab and recovered on an unspecified date in Apr2021 for a small scab there that was still kind of oozing a bit and unknown for rest of the events.  No follow-up attempts are needed. No further information is expected.
About day after booster Pfizer dose, neck stiffness Right side only, 3 days slight heat and muscular pain at right deltoid/injection site, then slight edema supraclavicular right side. Did not check axilla as never had lymphatic involvement after other vaccinations. Concern is more accumulation of fluid at ipsilateral side only of booster shot 5+ days after injection posterior neck and base of occiput. At peak very noticeable as could feel mass/edema Limiting cervical extension. As of today, base of occiput edema slowly going down after some  lymphedema MLD massage.  Another healthcare co-worker reported headaches.
fatigue/Just extremely tired; I feel horrible; This is a spontaneous report from a contactable consumer or other non hcp (patient) via Pfizer-sponsored program. A female patient of an unspecified age received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, formulation: solution for injection) via an unspecified route of administration on 04Feb2021 as single dose for covid-19 immunisation. On an unspecified date, the patient previously received first dose of bnt162b2 via unknown route of administration as single dose for covid-19 immunisation. The patient's medical history and concomitant medication were not reported. On unknown date, the patient feels horrible, fatigue, her appetite was okay. Just extremely tired and the patient wants to know if this was okay. The outcome of the events was unknown.  Information on about lot/batch number has been requested.  Follow-up attempts completed. No further information expected.
MY ARM IS IN SERIOUS PAIN ALL DOWN MY ARM INTO MY FINGERS , FEELS LIKE POSSABLE NERVE DAMAGE NOT SURE PAIN WILL NOT GO AWAY AND SEAMS TO GET WORST EACH DAY , LOSS OF STRENTH WITHIN ARM FUCTION
Patient is a 43 y.o. female patient, MD with history of CKD, currently on HD, recurrent pancreatitis, recent pancreatic pseudocyst, recent c diff colitis, chronic anemia, presented with shortness of breath.     Acute hypoxic respiratory failure Bilateral pleural effusions Possible volume overload Placed on BiPAP in the ED BNP 169,454 Chest x-ray with bilateral opacities concerning for edema however improved from previous CXR on 10/15 CT chest with small bilateral pleural effusions, multilobar airspace disease consistent with an acute inflammatory infectious process/atypical multilobar pneumonia Patient had full HD session with adequate fluid removal but still hypoxic BiPAP now weaned to room air Pulmonary consulted.  Appreciate input. Acute respiratory failure with hypoxia likely due to volume overload and COVID infection. Recommend to increase fluid removal with dialysis if tolerated. Continue Decadron and Mucinex. Okay to DC home from pulmonary standpoint.  Patient stable so will DC home.  Advised is to follow-up with her PCP. Patient is scheduled for outpatient HD tomorrow.   Covid-19 virus infection Viral pneumonia.   Date of onset of symptoms: 10/15 Symptoms present on admission: Shortness of breath.   Date of covid positive test: 10/18/22. Vaccination status: vaccinated Imaging: CT non-contrast chest, multifocal infiltrate.   Oxygen requirements on admission: BiPAP.   Current oxygen requirements: RA < BiPAP  Medical therapy: steroids  Dexamethasone started on 10/18.   Consultants following: ID. Anticipated special isolation end date: TBD.   No remdesivir due to renal failure. Pro-calcitonin elevated 0.6.  Discussed with ID.  Recommend Levaquin 750 mg every 48 hours x 7 days.   ESRD.  Currently on HD.   Nephrology consult for T-T-Sa HD.     Elevated troponin.   59 and 60.  Chronic.  Probably due to renal failure.
Pt received smallpox vaccine in L deltoid. He reports scratching the vaccination site with his R hand and developed induration with eschar formation on his R thumb. Eschar similar in appearance to L detoid innoculation site eschar. Pt reports biting his fingernails. He has a R thumb paronychia with cellulitis and lymphatic streaking proximally to R forearm and B/L axillary and inguinal LAD. Clinical diagnosis of R thumb autoinoculation with paronychia/cellulitis presumed to be GAS. Treated with IM ceftriaxone and PO clindamycin.
MMR vax recvd on 21JUN91; 2JUL91 "spotches" on head, face & torso, h/a, dizziness; 16JUL91 aching wrists, hands, ankles & back;
Information has been received from a licensed practical nurse concerning a patient who on 30-OCT-2007 was vaccinated SC with a 0.65 mL dose of varicella virus vaccine live (Oka/Merck) instead of zoster vaccine live (Oka/Merck). The varicella virus vaccine live (Oka/Merck) was reconstituted with 0.65 mL of diluent and administered. The patient was seen at the office. There was no product quality complaint. Follow-up information from the nurse stated that the patient was inadvertently given varicella virus vaccine live (Oka/Merck) instead of zoster vaccine live (Oka/Merck) because the two products were at the same location side by side and the nurse was new. The site has since then stored the two products in separate and labeled locations. The patient did not experience any adverse experience. No other information given. Follow-up information has been received concerning an 82-year old retired female with osteoporosis and degenerative arthritis, who has no no known allergies. On 30-OCT-2007 at 15:50, the patient was vaccinated in the left arm with a first intramuscular dose (previously reported as subcutaneous) of varicella virus vaccine live (Oka/Merck) (lot# 658287/1173U). On 27-Nov-2007, the patient was vaccinated intramuscularly in the left arm with a first dose of zoster vaccine live (Oka/Merck) (lot# 658212/0887U). Concomitant medications included aspirin, vitamin D and Evista. There was no illness at the time of vaccinations. No adverse events were noted. Follow up information has been received which indicates that there is no further information to report. Follow-up information has been received which stated "no adverse reaction was noted. No further information at this time." No further information is available.
Case went to have pacemaker replaced, had COVID test done per pre-op policy, was found to be positive.  Case denies symptoms
tongue swelling; tingling on tip of tongue; tired; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of SWOLLEN TONGUE (tongue swelling), PARAESTHESIA ORAL (tingling on tip of tongue), FATIGUE (tired) and VACCINATION SITE PAIN (sore arm) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history.).    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SWOLLEN TONGUE (tongue swelling), PARAESTHESIA ORAL (tingling on tip of tongue), FATIGUE (tired) and VACCINATION SITE PAIN (sore arm). At the time of the report, SWOLLEN TONGUE (tongue swelling), PARAESTHESIA ORAL (tingling on tip of tongue), FATIGUE (tired) and VACCINATION SITE PAIN (sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Concomitant product use was not provided by the reporter. Treatment included Benadryl and prednisone.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Patient is extremely fatigued, per patient "zero energy," bed bound for 4 days, are soreness and achy legs and diarrhea
Appearance of red spots on knees and lower legs on 11/17. Slight progression of spots on calves. Seemed like it was an allergic reaction to a newly purchased body wash. Discontinued use of body wash. On 11/26, I received intravenous toradol and reglan with oral meclizine and Benadryl to address a severe headache and nausea  that started on 11/24 and would not subside. The red spots increased on 11/28 to  my trunk, thighs, and elbows. The dermatologist did a biopsy and the results were returned today, 12/3. The spots have spread to my ankles and feet as well. I have been diagnosed with leukocytoclastic vasculitis. I started a regiment of prednisone today which will be  scheduled to end in 5 weeks. Overall symptoms include hard red spots which turn  reddish purple with long bouts of sitting or standing. My legs, ankles, and feet have swelling and throb. The swelling subsides significantly after sleeping for the night.
Client was given Moderna Booster dose instead of Moderna Bivalent Booster dose. No reactions noted.
Severe chills (teeth chattering and shaking), temperatures ranging from 101.5-103.0 throughout the day (2 am - current time 2:45 pm), severe fatigue and body aches (trouble standing and opening eyes), bluish fingernail beds with numbness and tingling to knocking knuckles.  2x taken excedrin which did break fever first time for temporary relief.  Moving arms and fingers to encourage circulation.
Headache and mild body ache/fatigue. Soreness and discomfort at injection site. Almost all symptoms gone within one day.
She received the 3rd dose of the COVID-19 vaccine in mid-January 2022. About two months later, she started experiencing finger pain and swelling along with morning stiffness. She was evaluated by pediatric rheumatology on 4/25/2022; at that time, she was found to have on physical exam signs of arthritis of  most of her fingers. She was diagnosed with polyarticular juvenile idiopathic arthritis and was started on methotrexate and etanercept therapy.  Her response to therapy will be determined at her next follow up visit in early August 2022.
One of our Medical Assistants gave a dose of expired Moderna Covid-19 vaccine.; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (One of our Medical Assistants gave a dose of expired Moderna Covid-19 vaccine.) in a 61-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045L21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 16-Jul-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Jul-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (One of our Medical Assistants gave a dose of expired Moderna Covid-19 vaccine.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (One of our Medical Assistants gave a dose of expired Moderna Covid-19 vaccine.) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. Patient received second booster dose on 16-Jul-2022. Number of doses/vials were reported as 1 dose. The vial did not undergo any temperature excursions. No treatment information was provided.
Pt had first dose of moderna at facility. Pt age 17. in error. MD wanted 2nd dose to be given at facility
Rash on neck and chest; This is a spontaneous report from a contactable consumer, the patient. A 79-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Mar2021 at 13:00 (at the age of 79-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and unspecified allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On an unknown date in 2021, the patient experienced rash on neck and chest, which lasted for 10 days. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event rash on neck and chest was resolved on an unknown date in 2021, after the duration of 10 days.  The lot number for BNT162b2 was not provided and will be requested during follow up.
I gave a dose of Pediatric, adol HEP B GSK to an adult so she did receive only a .5mg.  We will call her back to the health dept to receive a 2nd dose of adolescent HEP B.  She has insurance that will cover the cost of vaccine.  Error occurred by getting wrong vaccine out of the fridge and not triple checking.  As always I should of checked, double checked, and triple checked.  Error was discovered on data entry.  HEP B was a GSK product lot number AHBVB762CA.  We will call her back to the health dept to receive a 2nd dose of adolescent HEP B.
12 hour after vaccine employee developed bilateral leg numbness and pain along with  bodyaches, fatigue, headache ,N/v and fever. 5 days later above resolved except for fatigue and leg pains. she states both remaining symptom became worse and bruising develpoed to both legs. by 9-6 2021l eft leg symptom resolved and fatuge improved  but still persist along with bruising to lower legs.
After administering flu and Pfizer vaccine at around 1205, noticed that patient was not getting up to leave. He stated he was dizzy and his vision was getting dark. He also felt clammy and pale.    Asked if he had eaten anything today and he said no. Checked and O2 sat was 99% at 10L, HR 90, BP 98/77 L arm sitting. He also stated fingers on both hands were a little tingly.   Gave juice to drink. After several minutes, Patient stated he was doing good and was able to stand up and walk with assistance to the cot and stayed there for further assessment and   observation. Girlfriend was with patient at the time of incident.  Patient ambulated to the observation cot with assistance, oxygen had been removed. He was instructed to lay down with his feet up on a box.  12:15 his vitals while laying down were 112/68, 83 HR, 97%02 on Room Air. 12:18 Patient was instructed to sit on the side of the cot. He was given crackers to eat. 12:19 vitals while sitting were 120/82, 75 HR, 98% 02 on Room Air 12:25 75 HR 98% 02 on Room Air 12:30 Patient instructed to stand beside the cot vitals were 122/80, 84 HR, 98% Patient was instructed to sit in a chair. He ambulated to the chair without assistance. He remained stable and stated he was feeling much better. He requested to leave at 12:40p and he left with his girlfriend without assistance.
Fever 104 an bleeding around left pupil with red vessels of eye. No changes in vision, no nausea, no vomiting, no swelling
The patient called on 11/4/2010 and reported muscle aches and tightness in her shoulder muscle (trapezius muscle, not deltoid) and top of her forearm. She stated that it was relieved minimally by heat and Tylenol. She does not have a local doctor and was hesitant to go to doctor due to cost. I called patient back the morning of 11/5/2010 and she states that symptoms are spreading down torso on left side (same as injection). Explained Guillain Barre syndrome and advised patient to seek immediate attention at hospital.
Patient went home and reaction started right away, itching all over, rapid heart beat, rash all over body. Patient started taking diphenhydramine  every 4 hours. It game mild relief but did not stop the rash or intense itching or rapid heart beat. Patient went to her doctor the next day and she prescribed Hydroxyzine 25mg every 4 hours. She has been taking that as prescribed but the reaction is still continuing and patient has been impacted with work and employer is pressuring her to get 2nd shot of Pfizer. She is afraid to do so and it does not seem appropriate for her to get 2nd covid shot. She would like to get a medical exemption for work without the 2nd vaccination.
Swollen lymph nodes; This case was reported by a consumer via call center representative and described the occurrence of lymphadenopathy in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 8th November 2021, the patient received the 1st dose of Shingrix (intramuscular) 50 µg. On an unknown date, several days after receiving Shingrix, the patient experienced lymphadenopathy. On an unknown date, the outcome of the lymphadenopathy was unknown.   It was unknown if the reporter considered the lymphadenopathy to be related to Shingrix.  Additional details were provided as follows: The case was self reported by the patient. The patient received Shingrix into his left arm. Several days after receiving Shingrix, the patient experienced swollen lymph nodes but stated that he was not sure if it was due to the vaccine. The reporter did not have the lot number or expiration date of the vaccine administered The reporter gave consent to contact health care professional (HCP) but could not provide the HCP demographics requested. The reporter consented to follow up.
Some of the vaccine squirted out; This case was reported by a nurse via call center representative and described the occurrence of incomplete dose administered in a 1-year-old male patient who received HAV (Havrix) (batch number 95EJ7, expiry date 6th February 2023) for prophylaxis.   On 9th May 2022, the patient received Havrix. On 9th May 2022, unknown after receiving Havrix, the patient experienced incomplete dose administered. On an unknown date, the outcome of the incomplete dose administered was unknown.   Additional Information: GSK Receipt Date: 10-MAY-2022 Reporters comment: While administering Havrix vaccine to the patient, some of the vaccine squirted out. The patient received Havrix in left thigh. The reporter consented to follow up. Additional supportive information: While administering Havrix vaccine to the patient, some of the vaccine squirted out, which led to incomplete dose administered.
Engerix B below recommended temperature, administered; This case was reported by a other health professional via call center representative and described the occurrence of incorrect product storage in a patient who received HBV (Engerix B) for prophylaxis.   On 22nd April 2022, the patient received Engerix B. On an unknown date, unknown after receiving Engerix B, the patient experienced incorrect product storage. On an unknown date, the outcome of the incorrect product storage was unknown.   Additional Information: GSK Receipt Date: 11-May-2022 Reporter's comments: Engerix-B vaccines went below recommended temperature range on 21st March 2022.  The lowest temperature was 30.2F.  The readings were then ranging from 32.9F to 41.8F.  The duration was 7 hr. 45 min.  A dose was subsequently administered.  The reporter did not have lot number, expiration date, or patient information aside from initials. Till the time of reporting, a repeat dose had not been administered. The reporter consented to follow up. Additional Supportive Information: The patient received incorrectly stored vaccine, which led to product storage error.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022077006:Same reporter US-GLAXOSMITHKLINE-US2022077007:Same reporter US-GLAXOSMITHKLINE-US2022077005:Same reporter US-GLAXOSMITHKLINE-US2022077009:Same reporter
Pt stated that after she received her flu shot she developed a large red area on her arm.  This has occurred previously but this time she also had large hives in this area as well.  She was afraid that this was because she received Moderna shot 2 weeks early.
flu; Initial information received on 10-Dec-2022 regarding an unsolicited valid social media non-serious case from a consumer/non-hcp.  This case involves an unknown age and unknown gender patient who experienced flu after receiving vaccine influenza vaccine.  The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication and family history were not provided. It is unknown if the patient had any medical history, concomitant disease or risk factor.    On an unknown date, the patient received suspect influenza vaccine produced by unknown manufacturer at an unknown dose (lot number, expiry date: not reported) via unknown route in unknown administration site for prophylactic vaccination (immunisation).  On an unknown date the patient developed a non-serious flu (influenza) (unknown latency) following the administration of influenza vaccine.  It is unknown if there were lab data/results available.  Action taken: Not applicable.  Corrective treatment: Not reported.  Outcome: Unknown for the event flu.
Small bumps on leg and side; The following information was received from a healthcare professional on 20 Aug 2019.  A male received one dose of a Japanese encephalitis vaccine (batch number not reported) on an unknown day.  On the next day he experienced small bumps on his leg and side. Outcome was not reported.  ---  Follow up information was received from a healthcare professional on 23 Aug 2019.  Vaccinee initials and date of birth as well as batch number JEV18G84E were provided [batch number confirmed IXIARO as suspect drug]; Sender's Comments: Causality assessed as possible given the kind of event, which is well known and time to onset (next day).  ---  Causality assessment not changed, as no new information concerning the assessment was provided.
On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport  refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State  for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Nosebleed began 5 minutes after administering Flumist. Nosebleed easily controlled and patient able to go home without any further treatment.